MedTrace Logo

Biomarker Discovery for Novel Drug Development in Idiopathic Pulmonary Fibrosis

NCT01718990 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2020-07-31

No results posted yet for this study

Summary

Drug discovery can take many years especially since most studies to measure effectiveness depend on clinical outcomes like pulmonary function tests and hospitalizations.

This is an observational study designed to collect information, blood, and bronchoalveolar lavage fluid in people who have IPF and those who do not. The people who have IPF will be followed for 12 months to collect more biological samples and record clinically relevant information.

The goal of this study is to identify new molecular markers that are measurable and reliable in people who have IPF. It is hoped that these markers can be used in future drug studies to significantly speed up the process of finding drugs that help.

Conditions

  • Idiopathic Pulmonary Fibrosis (IPF)

Sponsors & Collaborators

Principal Investigators

  • Harold Collard, MD · University of California, San Francisco

Eligibility

Min Age
35 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2018-06-30
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01718990 on ClinicalTrials.gov